[go: up one dir, main page]

LTC2137143I2 - Pleuromutilino dariniai, skirti mikrobų sukeltų ligų gydymui - Google Patents

Pleuromutilino dariniai, skirti mikrobų sukeltų ligų gydymui

Info

Publication number
LTC2137143I2
LTC2137143I2 LTPA2020531C LTPA2020531C LTC2137143I2 LT C2137143 I2 LTC2137143 I2 LT C2137143I2 LT PA2020531 C LTPA2020531 C LT PA2020531C LT PA2020531 C LTPA2020531 C LT PA2020531C LT C2137143 I2 LTC2137143 I2 LT C2137143I2
Authority
LT
Lithuania
Prior art keywords
treatment
microbial diseases
pleuromutilin derivatives
pleuromutilin
derivatives
Prior art date
Application number
LTPA2020531C
Other languages
English (en)
Original Assignee
Nabriva Therapeutics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38668870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTC2137143(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nabriva Therapeutics GmbH filed Critical Nabriva Therapeutics GmbH
Publication of LTPA2020531I1 publication Critical patent/LTPA2020531I1/lt
Publication of LTC2137143I2 publication Critical patent/LTC2137143I2/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/61—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/93—Spiro compounds
    • C07C2603/95—Spiro compounds containing "not free" spiro atoms
    • C07C2603/98—Spiro compounds containing "not free" spiro atoms containing at least one ring with more than six ring members
    • C07C2603/99—Spiro compounds containing "not free" spiro atoms containing at least one ring with more than six ring members containing eight-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
LTPA2020531C 2007-03-20 2020-10-22 Pleuromutilino dariniai, skirti mikrobų sukeltų ligų gydymui LTC2137143I2 (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07450053A EP1972618A1 (en) 2007-03-20 2007-03-20 Pleuromutilin derivatives for the treatment of diseases mediated by microbes
PCT/AT2008/000097 WO2008113089A1 (en) 2007-03-20 2008-03-19 Pleuromutilin derivatives for the treatment of diseases mediated by microbes
EP08714294A EP2137143B1 (en) 2007-03-20 2008-03-19 Pleuromutilin derivatives for the treatment of diseases mediated by microbes

Publications (2)

Publication Number Publication Date
LTPA2020531I1 LTPA2020531I1 (lt) 2020-11-10
LTC2137143I2 true LTC2137143I2 (lt) 2023-10-10

Family

ID=38668870

Family Applications (1)

Application Number Title Priority Date Filing Date
LTPA2020531C LTC2137143I2 (lt) 2007-03-20 2020-10-22 Pleuromutilino dariniai, skirti mikrobų sukeltų ligų gydymui

Country Status (31)

Country Link
US (12) US20090118366A1 (lt)
EP (3) EP1972618A1 (lt)
JP (2) JP5479114B2 (lt)
KR (1) KR101478593B1 (lt)
CN (2) CN104211624B (lt)
AT (1) ATE523486T1 (lt)
AU (1) AU2008229609B2 (lt)
BR (1) BRPI0809023B8 (lt)
CA (1) CA2678795C (lt)
CY (2) CY1117482T1 (lt)
DK (2) DK2380874T3 (lt)
EA (1) EA018707B1 (lt)
ES (2) ES2620459T3 (lt)
FI (1) FIC20200038I1 (lt)
HR (1) HRP20110869T1 (lt)
HU (1) HUS2100001I1 (lt)
IL (1) IL200440A (lt)
LT (1) LTC2137143I2 (lt)
MA (1) MA31314B1 (lt)
MY (1) MY148916A (lt)
NL (1) NL301086I2 (lt)
NO (1) NO2021002I1 (lt)
NZ (1) NZ579011A (lt)
PL (1) PL2137143T3 (lt)
PT (2) PT2137143E (lt)
SI (1) SI2137143T1 (lt)
TN (1) TN2009000347A1 (lt)
TW (1) TWI406657B (lt)
UA (1) UA97836C2 (lt)
WO (1) WO2008113089A1 (lt)
ZA (1) ZA200905590B (lt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8092329B2 (en) 2005-08-31 2012-01-10 Wick Werks, LLC Bicycle chain rings with ramps
US8617015B2 (en) 2005-09-27 2013-12-31 Wick Werks, LLC Bicycle chain rings
EP1808431A1 (en) * 2006-01-16 2007-07-18 Nabriva Therapeutics Forschungs GmbH Mutilin derivatives and their use as pharmaceutical
EP1972618A1 (en) 2007-03-20 2008-09-24 Nabriva Therapeutics AG Pleuromutilin derivatives for the treatment of diseases mediated by microbes
EP2159220A1 (en) * 2008-09-02 2010-03-03 Nabriva Therapeutics AG Organic compounds
WO2010056855A1 (en) * 2008-11-13 2010-05-20 Teva Pharmaceutical Industries Ltd. Preparation of retapamulin via its pleuromutilin-thiol precursor
EP2399904A1 (en) * 2010-05-26 2011-12-28 Nabriva Therapeutics AG Process for the preparation of pleuromutilins
EP2390245A1 (en) * 2010-05-26 2011-11-30 Nabriva Therapeutics AG Enantiomerically pure amines
EP2433926A1 (en) * 2010-09-09 2012-03-28 Nabriva Therapeutics AG Pleuromutilin derivatives for use in the treatment of diseases mediated by microbes
BR112014001057B1 (pt) 2011-07-15 2018-07-03 Bayer Intellectual Property Gmbh Derivados de 2,3-difenilvaleronitrilo, processos para a sua preparação e sua utilização enquanto herbicidas e reguladores do crescimento vegetal
CN103265487A (zh) * 2013-06-05 2013-08-28 北京理工大学 截短侧耳素扩环衍生物及其制备方法和用途
CN104803911B (zh) * 2014-01-23 2018-01-05 中国科学院上海药物研究所 一类截短侧耳素化合物、其药物组合物、合成方法与用途
ES2553929B1 (es) * 2014-06-11 2016-09-26 Antonio Javier MORENO CASTRO Dispositivo de modificación/destrucción selectiva de tejidos orgánicos
WO2016202788A1 (en) * 2015-06-17 2016-12-22 Nabriva Therapeutics Ag Injectable pharmaceutical formulations of lefamulin
US20160367567A1 (en) 2015-06-18 2016-12-22 Mithra Pharmaceuticals S.A. Orodispersible dosage unit containing an estetrol component
PL3310333T3 (pl) 2015-06-18 2020-07-13 Estetra Sprl Ulegająca rozpadowi w jamie ustnej jednostka dawkowana zawierająca składnik estetrolowy
TWI762573B (zh) 2017-02-10 2022-05-01 奧地利商納畢瓦治療有限責任公司 截短側耳素之純化
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
CN111170911A (zh) * 2019-09-29 2020-05-19 安帝康（无锡）生物科技有限公司 用于治疗细菌感染性疾病的截短侧耳素类化合物
CN111170893B (zh) * 2020-01-19 2022-04-26 郑州依米花手性药物研究有限公司 Lefamulin的中间体化合物及其在Lefamulin制备中的应用
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
TW202204337A (zh) 2020-04-17 2022-02-01 奧地利商納畢瓦治療有限責任公司 截短側耳素類之醫療用途
JP2023522644A (ja) * 2020-04-17 2023-05-31 ナブリバ セラピューティクス ゲーエムベーハー プレウロムチリンの治療的使用
TW202203907A (zh) * 2020-04-17 2022-02-01 奧地利商納畢瓦治療有限責任公司 截短側耳素類的新醫療用途
CN117500809A (zh) * 2021-04-16 2024-02-02 纳布里瓦治疗有限责任公司 新的12-差向异构-莫林化合物及其用途
EP4475834A1 (en) 2022-02-09 2024-12-18 Nabriva Therapeutics GMBH Lefamulin and its derivatives for use in the treatment of a spiral shaped bacteria
EP4338732A1 (en) 2022-09-16 2024-03-20 Nabriva Therapeutics GMBH Lefamulin and its derivatives for use in the treatment of tularemia
WO2025081213A1 (en) 2023-10-21 2025-04-24 Ariva Med Gmbh NOVEL USES OF 12-EPI-MUTILIN COMPOUNDs

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4130709A (en) * 1977-12-08 1978-12-19 Eli Lilly And Company Pleuromutilin glycoside derivatives
DE4023848C2 (de) 1990-07-27 1994-04-21 Huels Chemische Werke Ag Verfahren zur Herstellung von 3-C¶1¶- bis C¶6¶-Alkoxycarbonylcyclohexanpropionsäureestern
GB9918037D0 (en) * 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
GB0017031D0 (en) * 2000-07-11 2000-08-30 Biochemie Gmbh Antimicrobials
GB0207495D0 (en) 2002-03-28 2002-05-08 Biochemie Gmbh Organic compounds
GB0209262D0 (en) 2002-04-23 2002-06-05 Biochemie Gmbh Organic compounds
WO2004011431A1 (en) * 2002-07-24 2004-02-05 Sandoz Ag Pleuromutilin derivatives as antimicrobbials
US7790767B2 (en) * 2005-06-27 2010-09-07 Nabriva Therapeutics Forschungs Gmbh Pleuromutilin derivatives containing a hydroxyamino- or acyloxyaminocycloalkyl group
GB0513058D0 (en) * 2005-06-27 2005-08-03 Sandoz Ag Organic compounds
GB0515995D0 (en) * 2005-08-03 2005-09-07 Sandoz Ag Organic compounds
EP1972618A1 (en) 2007-03-20 2008-09-24 Nabriva Therapeutics AG Pleuromutilin derivatives for the treatment of diseases mediated by microbes

Also Published As

Publication number Publication date
US8153689B2 (en) 2012-04-10
WO2008113089A1 (en) 2008-09-25
NZ579011A (en) 2011-03-31
UA97836C2 (ru) 2012-03-26
DK2137143T3 (da) 2012-01-02
US20170266194A1 (en) 2017-09-21
EA200970868A1 (ru) 2010-02-26
NO2021002I1 (no) 2021-01-15
US20100035987A1 (en) 2010-02-11
EP2137143B1 (en) 2011-09-07
CY2020032I2 (el) 2020-11-25
HK1140185A1 (en) 2010-10-08
BRPI0809023A2 (pt) 2014-09-23
NL301086I2 (nl) 2021-01-28
US20200281933A1 (en) 2020-09-10
CY1117482T1 (el) 2017-04-26
JP5893651B2 (ja) 2016-03-23
HUS2100001I1 (hu) 2021-03-01
CN104211624A (zh) 2014-12-17
CA2678795C (en) 2014-11-18
US20090118366A1 (en) 2009-05-07
CN104211624B (zh) 2017-12-15
MY148916A (en) 2013-06-14
CN101668738A (zh) 2010-03-10
PT2137143E (pt) 2011-12-22
BRPI0809023B8 (pt) 2021-05-25
SI2137143T1 (sl) 2012-01-31
US20210113571A1 (en) 2021-04-22
LTPA2020531I1 (lt) 2020-11-10
DK2380874T3 (en) 2017-03-27
TW200904402A (en) 2009-02-01
AU2008229609B2 (en) 2012-03-29
US20220218713A1 (en) 2022-07-14
EP1972618A1 (en) 2008-09-24
CY2020032I1 (el) 2020-11-25
KR101478593B1 (ko) 2015-01-02
EP2380874A2 (en) 2011-10-26
TN2009000347A1 (fr) 2010-12-31
KR20090123882A (ko) 2009-12-02
HRP20110869T1 (hr) 2011-12-31
JP2014159416A (ja) 2014-09-04
PL2137143T3 (pl) 2012-02-29
ES2375503T3 (es) 2012-03-01
US20130040954A1 (en) 2013-02-14
US20140256731A1 (en) 2014-09-11
US8071643B2 (en) 2011-12-06
US20200030335A1 (en) 2020-01-30
IL200440A0 (en) 2010-04-29
BRPI0809023B1 (pt) 2020-12-01
EP2137143A1 (en) 2009-12-30
US20120029072A1 (en) 2012-02-02
JP2010522143A (ja) 2010-07-01
EP2380874A3 (en) 2011-12-07
CA2678795A1 (en) 2008-09-25
EA018707B1 (ru) 2013-10-30
US20180303842A1 (en) 2018-10-25
IL200440A (en) 2013-09-30
FIC20200038I1 (fi) 2020-10-01
ES2620459T3 (es) 2017-06-28
TWI406657B (zh) 2013-09-01
EP2380874B1 (en) 2016-12-28
CN101668738B (zh) 2014-10-15
JP5479114B2 (ja) 2014-04-23
US20190175603A1 (en) 2019-06-13
ZA200905590B (en) 2010-10-27
PT2380874T (pt) 2017-04-03
MA31314B1 (fr) 2010-04-01
AU2008229609A1 (en) 2008-09-25
ATE523486T1 (de) 2011-09-15

Similar Documents

Publication Publication Date Title
LTC2137143I2 (lt) Pleuromutilino dariniai, skirti mikrobų sukeltų ligų gydymui
LTPA2020510I1 (lt) Pakeistieji 4-fenil-piridinai, skirti su NK-receptoriumi susijusių ligų gydymui
BRPI0911577A2 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
SMP200900085B (it) 3-imidazolil-indoli per il trattamento di malattieproliferative.
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
DK3456707T3 (da) 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
HUS1600048I1 (hu) Készítmény Fabry-kór kezelésére
DK2300443T3 (da) Triazolderivater, der er anvendelige til behandling af sygdomme
LT3251678T (lt) Benzoksaborolo dariniai, skirti bakterinių infekcijų gydymui
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
DK2056842T3 (da) Modificeret galactosylceramid til behandling af cancerøse sygdomme
HUE045367T2 (hu) Kombinált terápia diabétesz kezelésére
BRPI1009783A2 (pt) compostos para o tratamento de distúrbios metabólicos.
IT1391866B1 (it) Composizione iniettabile di polinucleotidi per il trattamento di patologie osteoarticolari.
BRPI0906606A2 (pt) Tratamento terapêutico para condições do pulmão.
DK2173831T3 (da) Brøndbehandling
BRPI0820410A2 (pt) Lactans substituídos terapêuticos
DK2117565T3 (da) Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme
PT2056804E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de doenças oculares
DK2296651T3 (da) 5-hydroxymethyl-oxazolidin-2-on-derivater til behandling af bakterielle intestinale sygdomme
BRPI0818598A2 (pt) agentes terapêuticos - 802
FI20095600L (fi) Koostumus ihosairauksien hoitoa varten
PL2293805T3 (pl) Kompozycja do ssania, do leczenia chorób zapalnych jamy ustnej i gardłowej
BRPI0909764A2 (pt) compostos terapêuticos
BRPI0912193A2 (pt) compostos terapêuticos.